Nemaura Medical Inc (FRA:N18A)

€ 0.115 0 (0%) Market Cap: 2.11 Mil Enterprise Value: 19.96 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100

Nemaura Medical Inc at Sidoti & Company November Virtual Micro-Cap Conference Transcript
Nov 15, 2023
Nemaura Medical Inc at Issuer Direct Winter Wonderland Best Ideas Investor Conference (Virtual) Transcript
Feb 22, 2023
Nemaura Medical Inc at Sidoti & Company January Micro-Cap Virtual Conference Transcript
Jan 19, 2023
Nemaura Medical Inc at Issuer Direct Planet MicroCap Showcase (Virtual) Transcript
Dec 07, 2022
Nemaura Medical Inc at Precious Metals Summit Planet Microcap Showcase Transcript
May 04, 2022
Nemaura Medical Inc at Benzinga Global Small Cap Investor Conference (Virtual) Transcript
Dec 08, 2021
Nemaura Medical Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021
Nemaura Medical Inc at Benzinga Virtual Global Small Cap Conference Transcript
May 14, 2021
Nemaura Medical Inc Positive Results from Head-to-Head Study with Major CGM Call Transcript
May 10, 2020

Nemaura Medical Inc at Precious Metals Summit Planet Microcap Showcase Transcript

May 04, 2022 / 04:00PM GMT

Release Date Price: €3.47 (+7.30%)

Transcript

Robert Kraft

Stock News Now - CEO

Welcome everyone to the Planet Microcap Showcase. I'm pleased to introduce our next presenter here at our event. It is Dr. Faz Chowdhury from Nemaura Medical, a publicly traded company. The symbol is NMRD on NASDAQ.

And with that, Dr. Chowdhury, thank you so much for joining us today.

Faz Chowdhury

Nemaura Medical Inc. - CEO

Thank you very much, Robert, and it's a pleasure to be speaking today. And I would like to thank Planet Microcap for the invitation to speak. So I'm Faz Chowdhury, as Robert mentioned, the CEO of Nomura Medical.

And first of all, just a few forward-looking statements, if you would. Let's go straight into what exactly is it that Nemaura Medical are focusing on as a company?

So the area that we are working within is the area of obesity and diabetes, which are currently two of the key drivers of the chronic disease epidemic. And now if you think about it, there are over half a billion people around the world with diabetes, and there are probably, in the region of three times

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.